---
search:
  boost: 3
---

# Anticonvulsants Rescue

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

## Decision Tree

- [CNS - Anticonvulsants, Rescue - Nayzilam, Valtoco](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQlYxSTAwSjRRUTZHNlRGQ0xDTjY0SEE4TSQlQCN0PWcu){ :target="_blank" rel="noopener"}

### Preferred

| Preferred              | Generic Name | Quantity | Time (Days) |
| :--------------------- | :----------- | :------: | :---------: |
| Diastat                |              |          |             |
| Diazepam Gel           |              |          |             |
| Nayzilam <sup>AR</sup> |              |          |             |
| Valtoco <sup>AR</sup>  |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
|               |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^one preferred^^ drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - Valtoco: a PA is required for patients younger than 6 years old </br>
**AR** - Nayzilam: a PA is required for patients younger than 12 years old

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com/:w:/g/personal/rachel_carpenter_gainwelltechnologies_com/EWN_d80YfxNHjWqwQ77mMfUB4JILmO6MEqvBSxlBn5-uug?e=mdkuXX24&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"}

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=32){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=15){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
